Cargando…
MET gene amplification is a mechanism of resistance to entrectinib in ROS1+ NSCLC
BACKGROUND: ROS1 tyrosine kinase inhibitors (TKIs) have demonstrated significant clinical benefit for ROS1+ NSCLC patients. However, TKI resistance inevitably develops through ROS1 kinase domain (KD) modification or another kinase driving bypass signaling. While multiple TKIs have been designed to t...
Autores principales: | Tyler, Logan C., Le, Anh T., Chen, Nan, Nijmeh, Hala, Bao, Liming, Wilson, Timothy R., Chen, David, Simmons, Brian, Turner, Kristen M., Perusse, Dean, Kasibhatla, Shailaja, Christiansen, Jason, Dudek, Arkadiusz Z., Doebele, Robert C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626307/ https://www.ncbi.nlm.nih.gov/pubmed/36101520 http://dx.doi.org/10.1111/1759-7714.14656 |
Ejemplares similares
-
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC
por: Drilon, Alexander, et al.
Publicado: (2022) -
Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC
por: Peters, T. L., et al.
Publicado: (2021) -
Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
por: Takakura, Toshiaki, et al.
Publicado: (2023) -
Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021) -
Correction to: Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC
por: Frampton, James E.
Publicado: (2021)